AptaBio Therapeutics Inc (293780) - Total Assets
Based on the latest financial reports, AptaBio Therapeutics Inc (293780) holds total assets worth ₩67.12 Billion KRW (≈ $45.49 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is AptaBio Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
AptaBio Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how AptaBio Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check 293780 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
AptaBio Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
AptaBio Therapeutics Inc's total assets of ₩67.12 Billion consist of 45.1% current assets and 54.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 33.0% |
| Accounts Receivable | ₩893.71 Million | 1.2% |
| Inventory | ₩224.87 Million | 0.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩39.35 Million | 0.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how AptaBio Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 293780 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AptaBio Therapeutics Inc's current assets represent 45.1% of total assets in 2024, a decrease from 96.9% in 2017.
- Cash Position: Cash and equivalents constituted 33.0% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
AptaBio Therapeutics Inc Competitors by Total Assets
Key competitors of AptaBio Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
AptaBio Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 2.50 | 54.60 |
| Quick Ratio | 1.24 | 2.50 | 54.60 |
| Cash Ratio | 0.00 | 1.84 | 0.00 |
| Working Capital | ₩5.02 Billion | ₩26.08 Billion | ₩42.94 Billion |
AptaBio Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between AptaBio Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.73 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -16.3% |
| Total Assets | ₩77.43 Billion |
| Market Capitalization | $88.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values AptaBio Therapeutics Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: AptaBio Therapeutics Inc's assets decreased by 16.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AptaBio Therapeutics Inc (2017–2024)
The table below shows the annual total assets of AptaBio Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩77.43 Billion ≈ $52.48 Million |
-16.31% |
| 2023-12-31 | ₩92.52 Billion ≈ $62.70 Million |
+64.88% |
| 2022-12-31 | ₩56.11 Billion ≈ $38.03 Million |
-13.55% |
| 2021-12-31 | ₩64.91 Billion ≈ $43.99 Million |
-13.96% |
| 2020-12-31 | ₩75.44 Billion ≈ $51.13 Million |
-2.53% |
| 2019-12-31 | ₩77.40 Billion ≈ $52.46 Million |
+280.77% |
| 2018-12-31 | ₩20.33 Billion ≈ $13.78 Million |
+84.77% |
| 2017-12-31 | ₩11.00 Billion ≈ $7.46 Million |
-- |
About AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more